A Phase II Study of Crenolanib Besylate Maintenance Following Allogeneic Stem Cell Transplantation in Patients With FLT3-positive Acute Myeloid Leukemia

Trial Profile

A Phase II Study of Crenolanib Besylate Maintenance Following Allogeneic Stem Cell Transplantation in Patients With FLT3-positive Acute Myeloid Leukemia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Jul 2016

At a glance

  • Drugs Crenolanib (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Sponsors AROG Pharmaceuticals
  • Most Recent Events

    • 13 Oct 2015 Planned primary completion date changed from 1 Aug 2017 to 1 Oct 2017 as reported by ClinicalTrials.gov record.
    • 13 Oct 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 10 Jun 2015 Planned primary completion date changed from 1 Jul 2017 to 1 Aug 2017 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top